Get the Stockscreener App
0.69
9.52%
0.06
Pre-market:
.69
Tela Bio Inc stock is traded at $0.69, with a volume of 238.27K.
It is up +9.52% in the last 24 hours and down -23.04% over the past month.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
See More
Previous Close:
$0.63
Open:
$0.6174
24h Volume:
238.27K
Relative Volume:
1.27
Market Cap:
$30.87M
Revenue:
$80.28M
Net Income/Loss:
$-38.83M
P/E Ratio:
-0.8295
EPS:
-0.8318
Net Cash Flow:
$-28.67M
1W Performance:
+11.29%
1M Performance:
-23.04%
6M Performance:
-56.05%
1Y Performance:
-29.59%
1-Day Range:
$0.6147
$0.7311
1-Week Range:
$0.5011
$0.79
52-Week Range:
$0.5011
$2.20
Tela Bio Inc Stock (TELA) Company Profile
Name
Tela Bio Inc
Sector
Industry
Phone
484-320-2930
Address
1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA
Compare TELA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELA
Tela Bio Inc
|
0.69 | 30.87M | 80.28M | -38.83M | -28.67M | -0.8318 |
ABT
Abbott Laboratories
|
101.83 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.07 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.42 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
61.86 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.84 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
Tela Bio Inc Stock (TELA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-31-22 | Initiated | Lake Street | Buy |
| Dec-03-19 | Initiated | Canaccord Genuity | Buy |
| Dec-03-19 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-19 | Initiated | Jefferies | Buy |
| Dec-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Tela Bio Inc Stock (TELA) Latest News
Stock Report: Is TELA Bio Inc attractive at current valuation2026 Spike Watch & Stepwise Swing Trade Plans - baoquankhu1.vn
Investment Analysts’ Weekly Ratings Updates for TELA Bio (TELA) - defenseworld.net
TELA Stock Price, Quote & Chart | TELA BIO INC (NASDAQ:TELA) - ChartMill
TELA Bio unveils new hernia solution with focus on simplicity and reliability - Traders Union
Aug Fed Impact: Is TELA Bio Inc a stock for growth or value investors2026 AllTime Highs & Safe Entry Trade Signal Reports - baoquankhu1.vn
Q3 2025 TELA Bio Inc Earnings Call Transcript - GuruFocus
Citizens Jmp Issues Pessimistic Forecast for TELA Bio (NASDAQ:TELA) Stock Price - Defense World
Published on: 2026-03-28 00:22:27 - baoquankhu1.vn
TELA Bio, Inc.Common stock - FinancialContent
TELA Bio analysts cut their forecasts after Q4 results - msn.com
TELA Bio, Inc. (NASDAQ:TELA) Q4 2025 earnings call transcript - MSN
Citizens cuts Tela Bio stock price target on commercial transition By Investing.com - Investing.com South Africa
Citizens cuts Tela Bio stock price target on commercial transition - Investing.com UK
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
Canaccord Genuity Group Lowers TELA Bio (NASDAQ:TELA) Price Target to $2.00 - defenseworld.net
Citizens JMP Maintains TELA Bio(TELA.US) With Buy Rating, Cuts Target Price to $3 - Moomoo
TELA Bio, Inc. (TELA) reports Q4 loss, lags revenue estimates - MSN
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), TELA Bio (TELA) and Nuvalent (NUVL) - The Globe and Mail
EPS Watch: What analysts say about TELA Bio Inc stock2026 Volatility Report & Consistent Income Trade Ideas - baoquankhu1.vn
TELA Bio (NASDAQ:TELA) Given New $1.00 Price Target at Piper Sandler - Defense World
TELA Bio (NASDAQ:TELA) Given New $2.00 Price Target at Lake Street Capital - Defense World
TELA Bio Analysts Cut Their Forecasts After Q4 Results - benzinga.com
Patterns Watch: Is TELA Bio Inc showing insider buyingWeekly Profit Analysis & Consistent Profit Trade Alerts - baoquankhu1.vn
TELA Bio 10-K: Revenue $80.3M, Net Loss $38.8M - TradingView
TELA Bio (NASDAQ: TELA) grows 2025 revenue 16% while investing heavily in R&D - Stock Titan
Piper Sandler Lowers Price Target for TELA Bio (TELA) to $1.00 | - GuruFocus
TELA Bio net loss hits USD 9M in Q4 2025 - Medical Buyer
TELA Bio (TELA) Rating Maintained but Price Target Lowered by An - GuruFocus
Piper Sandler cuts TELA Bio stock price target on lowered outlook - Investing.com Canada
Analyst Maintains 'Buy' Rating for TELA, Lowers Price Target to $2.00 | TELA Stock News - GuruFocus
Jefferies cuts TELA Bio stock price target on slower growth outlook - Investing.com UK
TELA Bio, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
TELA Bio, Inc. (NASDAQ:TELA) Q4 2025 Earnings Call Transcript - insidermonkey.com
Jefferies cuts TELA Bio stock price target on slower growth outlook By Investing.com - Investing.com South Africa
TELA Bio Inc (TELA) Q4 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
TELA Bio Inc (TELA) Q4 2025 Earnings Call Highlights: Record Rev - GuruFocus
Tela Bio Earnings Call: Growth Momentum, Cautious Outlook - tipranks.com
TELA Bio, Inc. (TELA) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
TELA Bio (TELA) Q4 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: TELA Bio Q4 2025 surprises with EPS beat but revenue miss - Investing.com
TelaBio (TELA) Reports Record Quarterly Revenue in Q4 - GuruFocus
TELA Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TELA Bio Q4 Net Loss Narrows, Revenue Rises - marketscreener.com
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
TELA Bio Inc (NASDAQ:TELA) Reports Record Q4 Revenue but Misses Sales Estimates - chartmill.com
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TELA Bio Posts Record 2025 Revenue, Sets 2026 Outlook - TipRanks
TELA BIO ($TELA) Releases Q4 2025 Earnings - Quiver Quantitative
Q4 2025 TELA Bio Inc Earnings Call Transcript - GuruFocus
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Tela Bio Inc Stock (TELA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):